Artificial Intelligence (AI) - From promise to practice
Reimagining Pharmacovigilance
Reinvent Drug Development and Safety with AI
AI and Computational Modeling Approaches for Dose Optimisation During Drug Development
Beyond Human Intuition
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Merck
Staff Engineer, Manufacturing Science and Technology, South East Asia
Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshooting and technical training for downstream processes Chan holds a degree in Chemical Engineering from the National University of Singapore
Articles
Determinants of Antimicrobial Resistance (AMR) Research in South East Asia
In the year Alexander Fleming made an outstanding medical history by discovering penicillin which helped to combat numerous deadly infections which previously had serious consequences upon human lives
Research Insights
Spectrophotometric And Spectroscopic Studies On Charge Transfer Complexes Of Antifungal Drug Clotrimazole
Abstract Clotrimazole CLZ is an imidazole derivative which is therapeutically used as an antifungal drug The routine control analysis of CLZ requires rapid reliable accurate and precise methods for the quantification of drug in its pharmaceutical formulations Spectrophotometric methods are presented for the determination of antifungal agent which were bas
Case Studies
Ambient Stable Biologics - Stable Aqueous Erythropoietin
Challenge Erythropoietin EPO is known to aggregate under heat stress which prevents storage of liquid compositions at ambient temperature The key challenge of this study was to demonstrate that the application of the ArestatT tools can reduce significantly aggregation of EPO at an elevated temperature compared with a marketed liquid formulation
Techno Trends
Bristol Myers Squibb Developed First-in class LPA1 Treatment for Progressive Pulmonary Fibrosis
Bristol Myers Squibb has developed BMS a potential firstinclass oral lysophosphatidic acid receptor LPA antagonist for the treatment of progressive pulmonary fibrosis
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Repurposed Drugs against the Latest Variants of Concerns of SARS-CoV-2
Sinosh Skariyachan Ph.D. is presently working as Assistant Professor in Microbiology at St. Pius X College, Rajapuram (Aided by Govt. of Kerala, India), Kasaragod, Kerala, India with more than 17 years of experience in teaching and research. One of his key areas of research is computational drug discovery and medicinal chemistry. He has published more than 75 international papers, book chapters, and text books. He is the editor of prestigious journals such as Computers in Biology and Medicine (Elsevier), Frontiers in Microbiology and a referee for more than 125 international journals. He received several awards and grants.
Envisioning the Biomanufacturing Facility of the Future
Merrilee is the Head of the BioContinuum™ Platform, driving the strategy and execution of Process Intensification Technologies, Software & Automation, and Analytics to meet the needs of biologics manufacturers. Throughout her 15 years at MilliporeSigma, she managed multiple product lines including clarification, aseptic, virus filtration, and Single Use & Systems.
Redefining Therapeutics
Professor Mads Hald Andersen, DMSc, DScTech, PhD, is Director of the National Center for Cancer Immune Therapy, CCIT-DK, at Copenhagen University Hospital Herlev, Denmark. He discovered tumor microenvironment antigens and anti-regulatory T cells and defined their role in immune regulation. He initiated the immune modulatory vaccine concept and has authored more than 250 publications and 25 patents.
Rethinking How Medicines Work
Dr. Asawari Pagare is a bioinformatician at UW Medicine where she studies the genomics of myositis, an autoimmune disease that is not yet well understood. She earned her PhD in Chemistry from the University of North Carolina at Chapel Hill, USA, where she explored how timing and fluctuations influence how living systems interpret signals relevant to medicine.
QSAR - Changing the Landscape of Antidiabetic Drug Discovery
Smriti Sharma Bhatia is an associate professor of chemistry at Miranda House, University of Delhi, India. Her academic and research interests include Computational chemistry and drug design. Currently, her research group is focused on the design of oral drug formulations for Type 2 diabetes mellitus. She is a popular science communicator.
press releasesRead more...
Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea (aflibercept), in Canada
Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA and Samsung Bioepis Co Ltd today announced that the companies have entered into a license and commercialization agreement for OPUVIZ aflibercept
WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
WuXi Biologics HK a leading global Contract Research Development and Manufacturing Organization CRDMO announced that its MFG drug substance manufacturing facility located in Hebei
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
Everest Medicines HKEX HK announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics Inc NASDAQ TVTX for the development
Fischer Medical Ventures Highlights Strategic Partnership as NYB.AI Showcased at NVIDIA GTC Taiwan 2026
Fischer Medical Ventures Limited FMVL today announced that its strategic partner Nanyang Biologics has achieved a significant international milestone with its AIpowered molecular research platform NYBAI
RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers
RoslinCT a leading global cell therapy Contract Development and Manufacturing Organization today announced a strategic partnership with BlueRock Therapeutics a leader in stem cell therapeutic development
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations
Merck a leading science and technology company today announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active
EventsRead more...
16 - 19
Jul 2026Bio Asia Taiwan 2026
Taipei Nangang Exhibition Cent...
20 - 22
Jul 20266th mRNA-Based Therapeutics Summit
The Westin Boston Seaport Dist...
20 - 22
Jul 2026Liquid Biopsy for Precision Oncology Summit
Boston, MA, USA
24 - 25
Jul 2026Cardiovascular Medicine Pharmacology 2026
Paris, France
26 - 30
Jul 2026ADLM 2026
Anaheim, CA USA
27 - 28
Jul 2026Pharmacovigilance & Drug Safety 2026
Rome, Italy
27 - 28
Jul 2026Pharmacology 2026
Rome, Italy
27 - 28
Jul 2026PharmaSci Innovations 2026
Rome, Italy
LATEST NEWSRead more...
Samsung Bioepis Enters into Agreement with Proteina for AI-Based Antibody Therapeutics Development
Samsung Bioepis has entered into a licence agreement with Proteina to collaborate on a governmentsupported national research and development RD initiative focused on developing artificial intelligence AIbased antibody therapeutics
Teva Enters into Agreement with Polpharma Biologics for Ocrelizumab Biosimilar Candidate
Teva Pharmaceuticals and Polpharma Biologics have entered into a global licensing agreement under which Teva will receive exclusive rights to commercialise both intravenous and subcutaneous formulations
Evogene and Tel Aviv University Launch AI-Driven Small-Molecule Drug Discovery Initiative
Evogene has entered into a strategic collaboration with the Blavatnik Center for Drug Discovery BCDD at Tel Aviv University to accelerate AIdriven smallmolecule drug discovery
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
Certara Inc a global leader in modelinformed drug development is partnering with NVIDIA to advance Certaras open integrated AI platform unifying its scientific software regulatory expertise and proprietary datasets
Bayer Enters into Partnership with University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado to Advance Drug Development and Clinical Trials
Bayer has formed a strategic partnership with the University of Colorado Anschutz UCHealth and Childrens Hospital Colorado to strengthen clinical research and accelerate drug development
OTR Therapeutics Enters into Collaboration with LG Chem to Advance Oncology Drug Development
OTR Therapeutics has entered into a strategic collaboration with LG Chem to identify evaluate and develop innovative oncology therapies originating from China The partnership aims to accelerate the development of promising cancer treatments
